Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BIIB

Biogen Inc

Feb 13 • 04:00PM ET

196.52

+1.02 0.52 %

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO IVV SPY VTV XLV IBB RSP VOE

Index	S&P 500	P/E	22.32	EPS (ttm)	8.81	Insider Own	0.18%	Shs Outstand	146.80M	Perf Week	-2.32%
Market Cap	28.84B	Forward P/E	12.12	EPS next Y	16.22	Insider Trans	-1.46%	Shs Float	146.44M	Perf Month	16.07%
Enterprise Value	31.68B	PEG	2.91	EPS next Q	3.04	Inst Own	93.44%	Short Float	3.20%	Perf Quarter	21.70%
Income	1.29B	P/S	3.03	EPS this Y	3.53%	Inst Trans	7.77%	Short Ratio	2.36	Perf Half Y	45.64%
Sales	9.53B	P/B	1.58	EPS next Y	2.50%	ROA	4.50%	Short Interest	4.69M	Perf YTD	11.67%
Book/sh	124.37	P/C	7.56	EPS next 5Y	4.16%	ROE	7.39%	52W High	202.41 -2.91%	Perf Year	41.94%
Cash/sh	26.00	P/FCF	14.06	EPS past 3/5Y	-25.04% -18.74%	ROIC	5.21%	52W Low	110.04 78.60%	Perf 3Y	-32.34%
Dividend Est.	-	EV/EBITDA	9.90	Sales past 3/5Y	0.35% -5.06%	Gross Margin	66.60%	Volatility	3.35% 3.22%	Perf 5Y	-29.32%
Dividend TTM	-	EV/Sales	3.32	EPS Y/Y TTM	-21.29%	Oper. Margin	25.39%	ATR (14)	6.08	Perf 10Y	-13.70%
Dividend Ex-Date	-	Quick Ratio	2.03	Sales Y/Y TTM	2.88%	Profit Margin	13.56%	RSI (14)	64.15	Recom	2.31
Dividend Gr. 3/5Y	- -	Current Ratio	2.68	EPS Q/Q	-118.25%	SMA20	8.58%	Beta	0.14	Target Price	208.77
Payout	0.00%	Debt/Eq	0.36	Sales Q/Q	-6.71%	SMA50	9.94%	Rel Volume	0.68	Prev Close	195.50
Employees	7500	LT Debt/Eq	0.36	Earnings	Feb 06 BMO	SMA200	31.68%	Avg Volume	1.99M	Price	196.52
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.45% 3.48%	Trades		Volume	1,352,247	Change	0.52%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-26	Reiterated	H.C. Wainwright	Buy	$194 → $228
Jan-07-26	Resumed	UBS	Neutral	$185
Dec-10-25	Downgrade	HSBC Securities	Hold → Reduce	$143
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300

Show Previous Ratings

Feb-13-26 11:22AM	Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus (MarketBeat)
10:27AM	Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans (MarketBeat)
09:57AM	Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 - Here's Why (Insider Monkey)
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
12:36AM	The 5 Most Interesting Analyst Questions From Biogen's Q4 Earnings Call (StockStory)
11:41PM	Loading…
Feb-12-26 11:41PM	1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky (StockStory)
Feb-11-26 05:00PM	Biogen Announces Board Chair Transition (GlobeNewswire)
04:47AM	Analyst Report: Biogen Inc. (Morningstar Research)
Feb-08-26 09:00PM	Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China (GlobeNewswire)
05:31PM	Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump (Benzinga)
Feb-07-26 12:31AM	BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds (StockStory)
Feb-06-26 07:43PM	Analyst Report: Biogen Inc. (Morningstar Research) +8.53%
04:02PM	Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst ... (GuruFocus.com)
03:48PM	Biogen stock pops, Robinhood gets lift as bitcoin ticks up (Yahoo Finance Video)
11:30AM	BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View (Zacks)
11:15AM	Loading…
11:15AM	Biogen Forecasts 2026 Profit Above Estimates as Shares Climb 30% (GuruFocus.com)
11:12AM	Pre-Markets Open in Green to Close the Week (Zacks)
10:33AM	Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump (Benzinga)
10:29AM	Pre-Markets Rebounding Ahead of Super Bowl Sunday (Zacks)
10:10AM	Biogen Q4 Earnings Call Highlights (MarketBeat)
09:42AM	Stock Market Today: Dow Rallies, Bitcoin Bounces; Amazon Dives On Earnings Results (Live Coverage) (Investor's Business Daily)
09:30AM	Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:59AM	Biogen Revenue Down as Multiple Sclerosis Sales Slide (The Wall Street Journal)
08:59AM	Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide (The Wall Street Journal)
07:35AM	Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. (Barrons.com)
07:17AM	Biogen's (NASDAQ:BIIB) Q4 CY2025: Strong Sales (StockStory)
07:15AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates (Zacks)
07:03AM	Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong (Investing.com)
06:09AM	How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat (Investor's Business Daily)
05:39AM	Consumer Sentiment, Biogen Earnings: What to Watch Friday (The Wall Street Journal)
05:35AM	Loading…
05:35AM	Stocks to Watch Friday: Amazon, Roblox, Stellantis, Strategy (The Wall Street Journal)
Feb-05-26 07:00PM	Under Armour earnings, Fed, Liftoff Mobile IPO: What to Watch (Yahoo Finance Video)
04:27AM	Amazon and Biogen Earnings: Still to Watch This Week (The Wall Street Journal)
Feb-04-26 10:02PM	Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
04:01PM	Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
07:30AM	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy (GlobeNewswire)
04:36AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-03-26 02:57PM	These Are The Worst 25 Stocks to Own in February (Schaeffer's Research)
10:00AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-30-26 10:00AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-29-26 04:09PM	Phillip Allen Sharp Improved Human Health With Breakthroughs (Investor's Business Daily)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
06:06AM	FDA grants breakthrough status to Biogen's litifilimab for CLE (Pharmaceutical Business Review)
Jan-28-26 12:47PM	Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. (Barrons.com)
07:30AM	Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options (GlobeNewswire)
Jan-25-26 06:30PM	FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review (PR Newswire)
06:30PM	FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review (GlobeNewswire)
Jan-22-26 09:00AM	Investors load Corxel with $287M for a differentiated obesity pill (BioPharma Dive)
Jan-20-26 08:28AM	3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 (MarketBeat)
Jan-14-26 08:46AM	What to Expect From Biogen's Next Quarterly Earnings Report (Barchart) -5.04%
Jan-13-26 11:45AM	JPM26: Biotechs M&A lift, the new Biogen and Mercks $70B target (BioPharma Dive)
09:11AM	Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy (CNBC TV)
03:02AM	Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 Transformational Era at JPMorgan Conference (MarketBeat)
Jan-12-26 11:05AM	Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy (GlobeNewswire)
Jan-11-26 11:05PM	3 Reasons to Sell BIIB and 1 Stock to Buy Instead (StockStory)
02:00PM	Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome (Business Wire)
Jan-10-26 02:57PM	Here's What Analysts Think About Biogen Inc. (BIIB) (Insider Monkey)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-05-26 08:00PM	Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China (GlobeNewswire)
01:52PM	Biotech and Pharma Stocks Tumble as Investors Race into Energy (Barrons.com)
07:02AM	Samsung Bioepis initiates Byooviz commercialisation in Europe (Pharmaceutical Business Review)
Jan-02-26 07:44AM	Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth (Zacks)
Dec-29-25 10:03AM	UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026 (Barrons.com)
Dec-28-25 03:00AM	5 Healthcare Themes for Investors to Watch in 2026 (Barrons.com)
Dec-22-25 11:20AM	The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS (GlobeNewswire)
Dec-21-25 10:31PM	Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers (StockStory)
Dec-19-25 11:50AM	Biogen (BIIB) Stock Trades Up, Here Is Why (StockStory)
Dec-17-25 05:13PM	HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress (Insider Monkey)
01:40PM	MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too? (Barchart)
Dec-16-25 01:15PM	Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% (Investor's Business Daily)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)
10:05AM	Lululemon Set to Exit Nasdaq 100 as Index Adds New Members (GuruFocus.com)
09:11AM	Western Digital stock rises after inclusion in Nasdaq-100 Index (Investing.com)
07:03AM	200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party (GuruFocus.com)
Dec-13-25 11:04AM	Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut (MarketWatch)
Dec-12-25 08:21PM	Bitcoin hoarding company Strategy remains in Nasdaq 100 (Reuters)
04:53AM	Analysts flag risks for Strategy at Nasdaq 100 index reshuffle (Reuters)
Dec-10-25 11:31PM	3 Healthcare Stocks We Think Twice About (StockStory)
12:40PM	ASH 2025: AbbVie and Genmabs Epkinly sets new standard in second-line FL (Clinical Trials Arena)
11:13AM	Fed Cuts Rates for Third Time This Year, Signals One More in 2026 (Barchart)
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
09:09AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More (24/7 Wall St.)
08:36AM	HSBC highlights one pharma stock to buy and one to sell for 2026 (Investing.com)
04:47AM	Health Canada approves Biogen's Zurzuvae for PPD treatment (Pharmaceutical Business Review)
Dec-08-25 06:30PM	"LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List (GlobeNewswire)
01:53PM	Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? (Zacks)
03:37AM	Is Biogen Stock Outperforming the Dow? (Barchart)
Dec-05-25 11:30AM	Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? (Zacks)
09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
09:00AM	Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire)
Dec-03-25 06:10PM	Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 (GlobeNewswire)
11:30AM	Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? (Zacks)
07:26AM	Tech Is Getting Left Behind in the S&P 500s Latest Rebound (Bloomberg)
Dec-02-25 04:40PM	New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF (PR Newswire)
Dec-01-25 07:30AM	Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
07:30AM	Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-27-25 07:30PM	Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI" for the Treatment of Early Alzheimer's Disease in Japan (GlobeNewswire)
Nov-26-25 05:30AM	Hedge Funds Pile Into Health Stocks Leading Market in Rotation (Bloomberg)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Viehbacher Christopher	President and CEO	Feb 06 '26	Option Exercise	0.00	24,461	0	36,548	Feb 10 05:06 PM
Singhal Priya	Head of Development	Feb 06 '26	Option Exercise	0.00	6,900	0	12,115	Feb 10 05:05 PM
Singhal Priya	Head of Development	Feb 09 '26	Sale	199.83	2,660	531,548	8,043	Feb 10 05:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 06 '26	Option Exercise	0.00	8,725	0	21,016	Feb 10 05:03 PM
Kramer Robin	Chief Financial Officer	Feb 06 '26	Option Exercise	0.00	5,003	0	12,535	Feb 10 05:02 PM
Keeney Adam	Head of Corporate Development	Feb 06 '26	Option Exercise	0.00	5,080	0	6,875	Feb 10 05:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 06 '26	Option Exercise	0.00	6,889	0	11,786	Feb 10 05:00 PM
Grogan Jane	Head of Research	Feb 06 '26	Option Exercise	0.00	3,258	0	4,642	Feb 10 04:59 PM
Gregory Ginger	EVP, Human Resources	Feb 06 '26	Option Exercise	0.00	7,183	0	23,491	Feb 10 04:58 PM
Godbout Sean	Chief Accounting Officer	Feb 06 '26	Option Exercise	0.00	1,079	0	1,395	Feb 10 04:56 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 06 '26	Option Exercise	0.00	9,046	0	43,321	Feb 10 04:55 PM
Singhal Priya	Officer	Feb 09 '26	Proposed Sale	199.83	2,660	531,548		Feb 09 10:14 AM
Singhal Priya	Head of Development	Jan 30 '26	Option Exercise	0.00	1,829	0	7,601	Feb 03 05:17 PM
Singhal Priya	Head of Development	Feb 02 '26	Sale	179.30	748	134,116	6,271	Feb 03 05:17 PM
Singhal Priya	Officer	Feb 02 '26	Proposed Sale	179.30	748	134,116		Feb 02 11:10 AM
Viehbacher Christopher	President and CEO	Dec 01 '25	Option Exercise	0.00	7,040	0	19,847	Dec 03 04:42 PM
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM
Godbout Sean	Chief Accounting Officer	Oct 02 '25	Option Exercise	0.00	26	0	503	Oct 06 01:00 PM
Singhal Priya	Head of Development	Aug 29 '25	Option Exercise	0.00	1,669	0	7,096	Sep 02 05:56 PM
Singhal Priya	Head of Development	Sep 02 '25	Sale	133.55	517	69,045	5,772	Sep 02 05:56 PM
Singhal Priya	Officer	Sep 02 '25	Proposed Sale	133.55	517	69,045		Sep 02 12:54 PM
Izzar Rachid	Head of Global Product Strat.	Jul 08 '25	Sale	135.00	2,223	300,105	6,330	Jul 16 05:55 PM
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM
Singhal Priya	Head of Development	May 19 '25	Sale	126.25	3,806	480,508	5,427	May 20 04:05 PM
Singhal Priya	Officer	May 19 '25	Proposed Sale	126.25	3,806	480,508		May 19 11:24 AM
Keeney Adam	Head of Corporate Development	May 01 '25	Option Exercise	0.00	938	0	2,838	May 05 04:19 PM
DORSA CAROLINE	Director	May 02 '25	Buy	122.72	1,235	151,559	27,842	May 05 04:17 PM
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM

NBIX Neurocrine Biosciences, Inc daily Stock Chart

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: VTI IJH VB VBK VXF MDY IBB XBI FBT IWP

Index	-	P/E	26.59	EPS (ttm)	4.67	Insider Own	2.67%	Shs Outstand	100.10M	Perf Week	-12.10%
Market Cap	12.46B	Forward P/E	16.49	EPS next Y	7.53	Insider Trans	-3.64%	Shs Float	97.69M	Perf Month	-8.28%
Enterprise Value	11.45B	PEG	0.60	EPS next Q	1.09	Inst Own	98.90%	Short Float	3.42%	Perf Quarter	-15.48%
Income	478.60M	P/S	4.35	EPS this Y	27.16%	Inst Trans	1.70%	Short Ratio	3.09	Perf Half Y	-5.48%
Sales	2.86B	P/B	3.82	EPS next Y	26.73%	ROA	11.13%	Short Interest	3.34M	Perf YTD	-12.49%
Book/sh	32.50	P/C	8.41	EPS next 5Y	27.58%	ROE	16.38%	52W High	160.18 -22.51%	Perf Year	6.20%
Cash/sh	14.75	P/FCF	16.64	EPS past 3/5Y	44.05% 2.31%	ROIC	13.05%	52W Low	84.23 47.36%	Perf 3Y	19.90%
Dividend Est.	-	EV/EBITDA	17.17	Sales past 3/5Y	24.32% 22.29%	Gross Margin	98.18%	Volatility	4.38% 3.12%	Perf 5Y	8.78%
Dividend TTM	-	EV/Sales	4.00	EPS Y/Y TTM	41.73%	Oper. Margin	22.25%	ATR (14)	4.60	Perf 10Y	244.40%
Dividend Ex-Date	-	Quick Ratio	3.30	Sales Y/Y TTM	21.45%	Profit Margin	16.73%	RSI (14)	30.92	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	3.39	EPS Q/Q	47.94%	SMA20	-8.35%	Beta	0.34	Target Price	177.29
Payout	0.00%	Debt/Eq	0.14	Sales Q/Q	28.33%	SMA50	-11.94%	Rel Volume	1.96	Prev Close	123.10
Employees	2000	LT Debt/Eq	0.13	Earnings	Feb 11 AMC	SMA200	-8.49%	Avg Volume	1.08M	Price	124.12
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.97% 1.90%	Trades		Volume	2,122,668	Change	0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$175
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130

Show Previous Ratings

Feb-12-26 02:38PM	Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance (Benzinga) -10.43%
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
08:30AM	Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:04AM	Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Loading…
05:30PM	Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
04:17PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
Feb-06-26 09:15AM	Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-26 10:00AM	Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-26-26 08:30AM	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
12:10PM	Loading…
Jan-22-26 12:10PM	Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-21-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results (PR Newswire)
Jan-15-26 08:30AM	Neurocrine Biosciences Presents Head-to-Head INGREZZA (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR (PR Newswire)
Jan-08-26 04:10PM	How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine (Investor's Business Daily)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technologies, and More (24/7 Wall St.)
Jan-05-26 04:01PM	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy (PR Newswire)
Dec-16-25 04:01PM	Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology (PR Newswire)
Dec-09-25 04:01PM	Neurocrine Biosciences to Host R&D Day on December 16 (PR Newswire)
Dec-05-25 08:03AM	Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level (Investor's Business Daily)
Nov-27-25 12:45PM	Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily) +5.61%
Nov-20-25 08:30AM	Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-11-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (Zacks)
04:05PM	Loading…
Nov-10-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
01:25PM	Neurocrine chalks up a depression drug failure (BioPharma Dive)
Nov-06-25 12:20PM	Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? (Zacks)
Nov-04-25 12:00PM	What Makes Neurocrine (NBIX) a New Strong Buy Stock (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)
07:30PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter (Investor's Business Daily)
04:19PM	Neurocrine Bio Surges After Crushing Third-Quarter Expectations (Investor's Business Daily)
04:06PM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-24-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
Oct-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) (Zacks)
Oct-22-25 05:15PM	USANA Health Sciences (USNA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules (PR Newswire)
Oct-07-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
Oct-06-25 04:05PM	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Sep-25-25 09:55AM	Should You be Optimistic on Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-24-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Sep-23-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden (PR Newswire)
Sep-22-25 08:30AM	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
Sep-16-25 04:05PM	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
02:58PM	What Does Wall Street Think About Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-02-25 04:03AM	Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access (Insider Monkey)
Aug-26-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-20-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-06-25 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-31-25 03:32AM	Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -6.24%
Jul-30-25 06:00PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:05PM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 11:40AM	CPRX vs. NBIX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-27-25 09:58AM	Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence (Insider Monkey)
Jul-25-25 11:28PM	Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating (Insider Monkey)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-15-25 10:57AM	Neurocrine shares new one-year data from trial of Crenessity for CAH (Clinical Trials Arena)
09:00AM	Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Analysis of CAHtalog Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 (PR Newswire)
Jul-14-25 04:35PM	Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting (PR Newswire)
08:30AM	Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY (crinecerfont) in Adult Patients, at ENDO 2025 (PR Newswire)
Jul-10-25 11:26PM	Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List (Insider Monkey)
08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-09-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results (PR Newswire)
Jun-30-25 04:05PM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist (PR Newswire)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Jun-23-25 11:40AM	EGO or AEM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 08:30AM	Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia (PR Newswire)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-09-25 04:05PM	Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer (PR Newswire)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-02-25 08:30AM	Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGREZZA (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia (PR Newswire)
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire)
May-29-25 12:03AM	Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched (Insider Monkey)
May-28-25 04:05PM	Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (PR Newswire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '26	Option Exercise	0.00	2,096	0	5,902	Feb 03 06:22 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '26	Option Exercise	0.00	2,294	0	54,047	Feb 03 06:21 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '26	Option Exercise	0.00	2,437	0	38,465	Feb 03 06:06 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '26	Option Exercise	0.00	1,741	0	28,599	Feb 03 06:05 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '26	Option Exercise	0.00	801	0	5,531	Feb 03 06:04 PM
Gano Kyle	Chief Executive Officer	Jan 31 '26	Option Exercise	0.00	2,927	0	143,334	Feb 03 06:03 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '26	Option Exercise	0.00	5,142	0	519,738	Feb 03 06:02 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '26	Option Exercise	0.00	2,373	0	49,127	Feb 03 06:01 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '26	Option Exercise	0.00	238	0	16,119	Feb 03 06:01 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Option Exercise	35.99	36,400	1,310,036	174,995	Jan 20 06:56 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Sale	132.70	36,400	4,830,458	140,407	Jan 20 06:56 PM
KYLE GANO	Officer	Jan 16 '26	Proposed Sale	133.35	36,400	4,853,940		Jan 16 04:21 PM
Lippoldt Darin	Chief Legal Officer	Jan 08 '26	Option Exercise	35.99	3,349	120,531	46,754	Jan 12 04:18 PM
Norwalk Leslie V	Director	Dec 15 '25	Option Exercise	91.07	10,000	910,742	12,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Sale	152.23	5,000	761,144	7,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 16 '25	Sale	155.09	1,190	184,558	6,239	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Proposed Sale	155.11	11,250	1,745,000		Dec 15 10:58 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Option Exercise	43.24	4,376	189,218	47,781	Dec 10 09:04 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Sale	159.65	4,376	698,615	43,405	Dec 10 09:04 AM
DARIN LIPPOLDT	Officer	Dec 08 '25	Proposed Sale	155.51	4,376	680,512		Dec 08 04:35 PM
LYONS GARY A	Director	Dec 03 '25	Option Exercise	47.89	15,000	718,350	135,482	Dec 04 04:14 PM
LYONS GARY A	Director	Dec 03 '25	Sale	152.61	15,000	2,289,082	120,482	Dec 04 04:14 PM
GARY A LYONS REVOCABLE LIVING	Director	Dec 03 '25	Proposed Sale	152.48	15,000	2,287,200		Dec 03 04:36 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Option Exercise	35.99	5,970	214,860	50,863	Dec 02 05:21 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Sale	151.74	5,970	905,881	44,893	Dec 02 05:21 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '25	Option Exercise	0.00	4,426	0	18,129	Dec 02 05:14 PM
ERIC BENEVICH	Officer	Nov 28 '25	Proposed Sale	151.58	5,970	904,933		Nov 28 01:20 PM
MORROW GEORGE J	Director	Nov 25 '25	Option Exercise	47.89	15,000	718,350	22,068	Nov 26 04:28 PM
MORROW GEORGE J	Director	Nov 25 '25	Sale	143.37	15,000	2,150,512	7,068	Nov 26 04:28 PM
GEORGE MORROW	Director	Nov 25 '25	Proposed Sale	141.25	15,000	2,118,750		Nov 25 04:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Option Exercise	47.89	18,000	862,020	58,360	Nov 06 05:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Sale	151.82	18,000	2,732,690	40,360	Nov 06 05:25 PM
Gano Kyle	Officer	Nov 04 '25	Proposed Sale	141.97	300	42,591		Nov 05 09:09 PM
WILLIAM H. RASTETTER	Director	Nov 05 '25	Proposed Sale	143.19	18,000	2,577,420		Nov 05 04:19 PM
Gano Kyle	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	613	0	140,720	Nov 04 08:18 PM
Gano Kyle	Chief Executive Officer	Nov 04 '25	Sale	141.97	300	42,591	140,407	Nov 04 08:18 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Option Exercise	35.99	106,322	3,826,529	620,918	Aug 11 04:55 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Sale	126.41	106,322	13,440,281	514,596	Aug 11 04:55 PM
KEVIN CHARLES GORMAN	Director	Aug 07 '25	Proposed Sale	128.43	106,322	13,654,934		Aug 07 04:24 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM
RASTETTER WILLIAM H	Director	May 05 '25	Option Exercise	42.76	30,000	1,282,800	67,491	May 07 07:05 PM
RASTETTER WILLIAM H	Director	May 05 '25	Sale	110.20	30,000	3,305,952	37,491	May 07 07:05 PM
WILLIAM H. RASTETTER	Officer	May 05 '25	Proposed Sale	109.68	30,000	3,290,400		May 05 04:40 PM

BIIB

Biogen Inc

NBIX

Neurocrine Biosciences, Inc

Upgrade your FINVIZ experience